Artiva Biotherapeutics, Inc.
HealthcareNASDAQ:ARTV · NASDAQ Global Market
+$0.54 today
Vol 1.43M · Avg 0.45M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$0 of revenue converted into -$87.1M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-3.55, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 -100.0% | $251.0K -99.3% | $33.5M +579.2% | $4.9M +146.3% | $2.0M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $2.6M | $0 | $0 | $0 | $0 | $725.6M | $804.0M | $882.4M |
| Gross Profit | -$2.6M -1134.7% | $251.0K -99.3% | $33.5M +579.2% | $4.9M +146.3% | $2.0M | $8.9B | $7.6B | $6.2B |
| Gross Margin | — | 100.0% +0.0pp | 100.0% +0.0pp | 100.0% +0.0pp | 100.0% | 9.8% | 28.9% | 38.3% |
| Research & Development | $69.5M +38.2% | $50.3M +0.2% | $50.3M +14.2% | $44.0M +3.7% | $42.4M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $20.3M +17.8% | $17.2M +23.7% | $13.9M -33.0% | $20.8M +61.5% | $12.9M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $88.0M +30.3% | $67.5M +5.3% | $64.2M -0.9% | $64.8M +17.2% | $55.3M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $2.6M +6.8% | $2.4M +7.3% | $2.3M +95.7% | $1.2M +366.9% | $248.0K | $374.2M | $1.2B | $631.8M |
| EBITDA | -$81.3M -45.0% | -$56.1M -121.1% | -$25.4M +55.6% | -$57.2M +20.1% | -$71.6M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | — | -22335.5% -22259.7pp | -75.7% +1083.8pp | -1159.5% +2415.7pp | -3575.3% | 5.6% | 46.3% | 42.0% |
| Operating Income | -$90.6M -34.7% | -$67.3M -119.4% | -$30.7M +48.7% | -$59.8M -12.3% | -$53.3M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | — | -26805.6% -26714.0pp | -91.6% +1121.7pp | -1213.3% +1447.6pp | -2660.9% | 16.6% | 24.1% | 22.0% |
| Interest Income | $6.0M +11.4% | $5.3M +111.0% | $2.5M +95.9% | $1.3M | $0 | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $0 | $0 | $0 | $0 | $0 | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | $6.7M -23.3% | $8.8M +188.4% | $3.0M +103.9% | $1.5M +108.1% | -$18.6M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$83.9M -43.4% | -$58.5M -111.7% | -$27.6M +52.6% | -$58.3M +18.8% | -$71.8M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | — | -23304.0% -23221.5pp | -82.5% +1100.5pp | -1183.0% +2404.6pp | -3587.7% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $0 | $0 -100.0% | $72.0K +35.8% | $53.0K | $0 | $1.3B | -$1.6B | $745.2M |
| Net Income | -$83.9M -43.4% | -$58.5M -111.2% | -$27.7M +52.6% | -$58.4M +18.7% | -$71.8M | $4.9B | $4.8B | $4.7B |
| Net Margin | — | -23304.0% -23221.3pp | -82.7% +1101.4pp | -1184.1% +2403.6pp | -3587.7% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$3 +34.0% | -$5 -337.0% | -$1 +64.2% | -$3 +18.6% | -$4 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$3 +34.0% | -$5 -337.0% | -$1 +64.2% | -$3 +18.6% | -$4 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $24.4M +0.3% | $24.4M +4.6% | $23.3M +32.4% | $17.6M +0.0% | $17.6M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $24.4M +0.3% | $24.4M +4.6% | $23.3M +32.4% | $17.6M +0.0% | $17.6M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Sutro Biopharma, Inc.
NASDAQ:STRO
$278.70M
Zentalis Pharmaceuticals, Inc.
NASDAQ:ZNTL
$266.95M
Shattuck Labs, Inc.
NASDAQ:STTK
$236.64M
ALX Oncology Holdings Inc.
NASDAQ:ALXO
$212.61M
Connect Biopharma Holdings Limited
NASDAQ:CNTB
$133.48M
InflaRx N.V.
NASDAQ:IFRX
$115.57M
Adverum Biotechnologies, Inc.
ADVM
$96.26M
Precision BioSciences, Inc.
NASDAQ:DTIL
$78.25M
Fractyl Health, Inc. Common Stock
NASDAQ:GUTS
$61.36M
Metagenomi, Inc. Common Stock
MGX
$45.18M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does ARTV generate?
Artiva Biotherapeutics, Inc. (ARTV) reported $0.00 of revenue in fiscal 2025.
Is ARTV profitable?
Artiva Biotherapeutics, Inc. (ARTV) reported -$83,865,000.00 of net income.
Explore More
Continue the stock analysis
Jump to another research area for this company.